Navigation Links
Cloud of smoke over Zyban

Can an anti-smoking drug be injurious to health? Pharma giant GlaxoSmithKline (GSK), under fire regarding its smoking cessation drug, Zyban, has risen in defence of its non-nicotine oral drug - in the wake of unproven reports in the UK, linking the drug to adverse reactions and deaths. //

Touted to be the world’s most successful smoking cessation drug, Zyban received a high decibel launch in India in June 2001. The cause for concern, however, was a safety update on the site of British regulatory body, Medicines Control Agency (MCA). The update, suggesting an unproven association between the tobacco-cessation drug and 57 deaths in the UK, spurred media-reports abroad casting a cloud over Zyban and subsequently causing a ripple effect in domestic circles.

Mr Kal Sundaram, GSK’s Director-Pharmaceuticals, told that regulatory bodies such as MCA of the UK and the FDA of the US have celared the drug and have said that “there were no reports directly linking the deaths to Zyban”. Zyban is a prescription drug and GSK would continue to sell it across world markets, he said. Endorsing the safety profile of Zyban, GSK said: “Death (the 57 reported deaths) was most commonly due to cardiovascular causes and where information on medical history was provided, most patients had a history of cardiovascular disease or risk factors for cardiovascular disease in addition to smoking.”

According to GSK reports in the UK, sales had slumped 34 per cent to 22 million pounds ($31 million) in the three months between October to September last year following media coverage of the reported deaths. Zyban, when launched, had come with its cautions saying: “For majority of smokers, side effects of Zyban are not a concern. Zyban is generally well tolerated. Side effects are mild and include dry mouth and insomnia.....should be used cautiously, if at all, in patients with seizure disorder and in those taking alcohol during treament.”
'"/>




Page: 1

Related medicine news :

1. Smokers Cloud Has A Silver Lining?
2. IMF considers Bird Flu to be a Dark Cloud
3. Half of worlds children are passive smokers - damning disclosure from WHO
4. Glaxo launches pills to help smokers quit in 7-12 weeks
5. Emotional trigger to smoke
6. Poor diet among smokers
7. Pregnant smokers could harm their child
8. Drinkers and smokers are at risk
9. A new method to help smokers quit
10. What makes young girls smoke
11. Poor diet among smokers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: